Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orexo AB

www.orexo.com

Latest From Orexo AB

Deal Watch: Roche And Vividion Will Investigate E3 Ligases In Cancer, Immunology

Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK

Deals Business Strategies

Orexo Files Alcohol Abuse Digital Therapy With US FDA

The Swedish firm is taking a multifaceted approach to treating substance use disorders such as alcohol addiction, by offering both medication and psycho-social support.

Digital Health Strategy

Deal Watch: Themis Leverages Measles Vector Platform In Collaboration With Merck & Co.

In its first big pharma deal, Austrian biotech will develop experimental vaccines for Merck against an undisclosed target. Innovent licenses Chinese rights to Lilly diabetes candidate, while Novartis gets option to Iconic’s preclinical ophthalmology program.

Deals Business Strategies

The Many Paths To Biotech CEO

There is no single path toward becoming a CEO. The job requires many different skills, often concurrently: sharp analytical capabilities, strategic thinking, clear communication with multiple audiences, curiosity and perseverance. It demands strong leadership but also humility, and a willingness to acknowledge mistakes and knowledge gaps.

C-Suite Speaks Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Diabact
  • Orexo Pharmaceuticals AB
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Orexo AB
  • Senior Management
  • Nikolaj Sorensen, CEO
    Michael Sumner, PhD, CMO
    Jesper Lind, COO
  • Contact Info
  • Orexo AB
    Phone: (46) 18 780 88 00
    P.O. Box 303 Uppsala, SE 751 05
    Sweden
UsernamePublicRestriction

Register